These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 25034050)

  • 1. Effects of aflibercept on primary RPE cells: toxicity, wound healing, uptake and phagocytosis.
    Klettner A; Tahmaz N; Dithmer M; Richert E; Roider J
    Br J Ophthalmol; 2014 Oct; 98(10):1448-52. PubMed ID: 25034050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative toxicity and proliferation testing of aflibercept, bevacizumab and ranibizumab on different ocular cells.
    Schnichels S; Hagemann U; Januschowski K; Hofmann J; Bartz-Schmidt KU; Szurman P; Spitzer MS; Aisenbrey S
    Br J Ophthalmol; 2013 Jul; 97(7):917-23. PubMed ID: 23686000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term treatment with anti-VEGF does not induce cell aging in primary retinal pigment epithelium.
    Schottler J; Randoll N; Lucius R; Caliebe A; Roider J; Klettner A
    Exp Eye Res; 2018 Jun; 171():1-11. PubMed ID: 29522724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single- and repeated-dose toxicity study of bevacizumab, ranibizumab, and aflibercept in ARPE-19 cells under normal and oxidative stress conditions.
    Saenz-de-Viteri M; Fernández-Robredo P; Hernández M; Bezunartea J; Reiter N; Recalde S; García-Layana A
    Biochem Pharmacol; 2016 Mar; 103():129-39. PubMed ID: 26793998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the efficacy of aflibercept, ranibizumab, and bevacizumab in an RPE/choroid organ culture.
    Klettner A; Recber M; Roider J
    Graefes Arch Clin Exp Ophthalmol; 2014 Oct; 252(10):1593-8. PubMed ID: 25047874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ranibizumab and Bevacizumab but Not Aflibercept Inhibit Proliferation of Primary Human Retinal Pigment Epithelium in vitro.
    Parisi L; Fuhrer R; Zinkernagel M; Enzmann V
    Ophthalmologica; 2019; 241(3):137-142. PubMed ID: 30001546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Capacity of aflibercept to counteract VEGF-stimulated abnormal behavior of retinal microvascular endothelial cells.
    Deissler HL; Lang GK; Lang GE
    Exp Eye Res; 2014 May; 122():20-31. PubMed ID: 24631334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of bevacizumab, ranibizumab and aflibercept on cell viability, phagocytosis and mitochondrial bioenergetics of retinal pigment epithelial cell.
    Sheu SJ; Chao YM; Liu NC; Chan JY
    Acta Ophthalmol; 2015 Dec; 93(8):e631-43. PubMed ID: 25975662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Ranibizumab, Bevacizumab, and Aflibercept on Senescent Retinal Pigment Epithelial Cells.
    Chae JB; Rho CR; Shin JA; Lyu J; Kang S
    Korean J Ophthalmol; 2018 Aug; 32(4):328-338. PubMed ID: 30091312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of bevacizumab, ranibizumab, and aflibercept on phagocytic properties in human RPE cybrids with AMD versus normal mitochondria.
    Vo TA; Abedi S; Schneider K; Chwa M; Kenney MC
    Exp Eye Res; 2018 Dec; 177():112-116. PubMed ID: 30071215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Long-term Anti-VEGF Treatment on Viability and Function of RPE Cells.
    Brinkmann A; Winkelmann K; Käckenmeister T; Roider J; Klettner A
    Curr Eye Res; 2022 Jan; 47(1):127-134. PubMed ID: 33998943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fc Receptor Inhibition Reduces Susceptibility to Oxidative Stress in Human RPE Cells Treated with Bevacizumab, but not Aflibercept.
    Ranjbar M; Brinkmann MP; Zapf D; Miura Y; Rudolf M; Grisanti S
    Cell Physiol Biochem; 2016; 38(2):737-47. PubMed ID: 26871551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compatibility of recombinant tissue plasminogen activator (rtPA) and aflibercept or ranibizumab coapplied for neovascular age-related macular degeneration with submacular haemorrhage.
    Klettner A; Grotelüschen S; Treumer F; Roider J; Hillenkamp J
    Br J Ophthalmol; 2015 Jun; 99(6):864-9. PubMed ID: 25740806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical investigations of intravitreal ziv-aflibercept.
    de Oliveira Dias JR; Badaró E; Novais EA; Colicchio D; Chiarantin GM; Matioli MM; Verna C; Penha FM; Barros NM; Meyer CH; Farah ME; Rodrigues EB
    Ophthalmic Surg Lasers Imaging Retina; 2014; 45(6):577-84. PubMed ID: 25423640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracellular bevacizumab reduces phagocytotic uptake in RPE cells.
    Klettner A; Möhle F; Roider J
    Graefes Arch Clin Exp Ophthalmol; 2010 Jun; 248(6):819-24. PubMed ID: 20169356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracellular pathways following uptake of bevacizumab in RPE cells.
    Aboul Naga SH; Dithmer M; Chitadze G; Kabelitz D; Lucius R; Roider J; Klettner A
    Exp Eye Res; 2015 Feb; 131():29-41. PubMed ID: 25533679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different effects of intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues of monkey eyes.
    Julien S; Biesemeier A; Taubitz T; Schraermeyer U
    Br J Ophthalmol; 2014 Jun; 98(6):813-25. PubMed ID: 24457369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of Fc-receptors in the uptake and transport of therapeutic antibodies in the retinal pigment epithelium.
    Dithmer M; Hattermann K; Pomarius P; Aboul Naga SH; Meyer T; Mentlein R; Roider J; Klettner A
    Exp Eye Res; 2016 Apr; 145():187-205. PubMed ID: 26773870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in Uptake and Intracellular Fate between Bevacizumab and Aflibercept after Repetitive Long-Term Treatment in the Retinal Pigment Epithelium.
    Borchers L; Roider J; Klettner A
    Ophthalmic Res; 2021; 64(3):369-388. PubMed ID: 33011724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of aflibercept on the viability and metabolism of ocular cells in vitro.
    Ammar DA; Mandava N; Kahook MY
    Retina; 2013 May; 33(5):1056-61. PubMed ID: 23266881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.